Welcome to our dedicated page for AC Immune news (Ticker: ACIU), a resource for investors and traders seeking the latest updates and insights on AC Immune stock.
AC Immune SA (NASDAQ: ACIU) generates frequent news flow as a clinical-stage biopharmaceutical company developing precision therapeutics and diagnostics for neurodegenerative diseases. Company updates often center on clinical trial progress for its active immunotherapies and small-molecule programs targeting misfolded proteins implicated in Alzheimer’s disease, Parkinson’s disease and other NeuroOrphan indications.
Investors following ACIU news can expect detailed reports on interim and top-line data from key studies, such as the Phase 2 VacSYn trial of ACI-7104.056 in early Parkinson’s disease and the Phase 2 ABATE and ReTain trials in Alzheimer’s disease. Recent releases have highlighted strong immunogenicity and favorable safety for ACI-7104.056, biomarker trends suggesting potential stabilization of Parkinson’s disease pathology, and peer-reviewed results for the Tau-targeting active immunotherapy ACI-35.030 published in eBioMedicine.
News items also cover AC Immune’s diagnostic imaging efforts, including preclinical and clinical updates on PET tracers like ACI-19626 for TDP-43 pathology, with data published in Nature Communications. Corporate communications frequently include quarterly financial results, cash runway disclosures, pipeline prioritization decisions, workforce adjustments, and information on collaborations with partners such as Janssen, Takeda and Lilly.
This ACIU news page aggregates these company-issued announcements and regulatory communications, giving readers a single place to review clinical milestones, scientific publications, conference presentations and strategic corporate actions. For those tracking AC Immune’s progress in precision prevention of neurodegenerative diseases, it provides an organized view of how the pipeline and partnerships are evolving over time.
AC Immune (NASDAQ: ACIU) announced that its Tau PET tracer, PI-2620, is advancing to late-stage clinical development for Alzheimer's Disease (AD) as confirmed by its partner, Life Molecular Imaging (LMI). AC Immune will receive a milestone payment from LMI. This promising Tau PET tracer shows high binding affinity for aggregated Tau, a key indicator of neurological decline. Phase 2 trial results presented at the Alzheimer's Association International Conference indicated that PI-2620 could accurately detect Tau deposits, aiding in early diagnosis and monitoring of cognitive impairment.
AC Immune (NASDAQ: ACIU) has received a new grant from The Michael J. Fox Foundation (MJFF) to advance its alpha-synuclein PET tracer, ACI-12589, bringing total funding to USD 3.7 million. This support enables enhanced clinical studies, following proof-of-concept data showcasing the tracer's ability to generate live images of alpha-synuclein in the human brain. If successful, ACI-12589 may become a pioneering diagnostic tool for Parkinson’s disease, facilitating the development of new therapies.
AC Immune SA (Nasdaq: ACIU) hosted a webinar featuring Dr. Cynthia A. Lemere discussing the potential of vaccines in treating Alzheimer's and Parkinson's diseases. The session highlighted their precision medicine approach, focusing on three clinical-stage vaccines targeting Tau, Abeta, and α-synuclein. Vaccines are positioned to provide long-lasting immunity and cost-effective treatment options. The company’s pipeline includes ACI-35.030, ACI-24.060, and ACI-7104, with expected clinical data disclosures in 2022, showcasing their commitment to combating neurodegenerative diseases.
AC Immune SA (Nasdaq: ACIU) will host a KOL webinar on August 24, 2022, at 10:00 AM ET, focusing on innovative vaccination strategies for Alzheimer's and Parkinson's diseases. The event will feature Dr. Cynthia A. Lemere from Brigham & Women's Hospital, discussing the immunotherapy landscape and biomarker selection. AC Immune's management will present their precision medicine approach and pipeline. A live Q&A session will follow the presentation. Registration is available online, with a replay planned for later viewing on the company's website.
AC Immune SA (Nasdaq: ACIU) announced the presentation of findings from the Alzheimer’s Prevention Initiative Autosomal Dominant Alzheimer’s Disease (ADAD) Colombia Trial at the Alzheimer’s Association International Conference. Crenezumab, the anti-amyloid beta antibody tested, was safe with no ARIA-E cases observed. Numerical differences favoring crenezumab over placebo were noted, but none reached statistical significance. The study's limitations included lower statistical power due to the population's demographics. All mutation carriers will continue receiving crenezumab as data is further analyzed.
AC Immune SA (NASDAQ: ACIU) announced significant clinical advancements and financial updates. The company has delivered three clinical readouts in 2022 and aims for four more by year-end. The first patient has been dosed in the Phase 1b/2 trial of its anti-Abeta vaccine ACI-24.060 targeting Alzheimer's and Down syndrome. Financially, AC Immune holds CHF 154.1 million, ensuring operations through Q1 2024. However, a net loss of CHF 19.6 million was reported for Q2 2022, slightly higher than the previous year's loss.
AC Immune SA (NASDAQ: ACIU) has announced its participation in the Alzheimer’s Association International Conference (AAIC) from July 31 to August 4, 2022, in San Diego. The company will present 10 findings, including new Phase 2 results for the Tau PET tracer PI-2620 and an innovative clinical trial design for ACI-24.060 aimed at Alzheimer's and Down syndrome patients. CEO Andrea Pfeifer emphasized the significance of these results in shifting treatment paradigms for neurodegenerative diseases, highlighting the collaboration with partners like Genentech.
AC Immune SA (NASDAQ: ACIU) held its Annual General Meeting in June 2022, where shareholders re-elected the Board of Directors. Douglas Williams continues as Chairman. The company reported progress in its pipeline, including interim Phase 1b/2a data for the anti-pTau vaccine ACI-35.030 and clinical proof-of-concept for an alpha-synuclein PET tracer. They remain on track for four additional clinical data readouts in 2022 and have sufficient cash for operations into 2024.
AC Immune SA (NASDAQ: ACIU) announced results from its Alzheimer’s Prevention Initiative Autosomal Dominant Alzheimer's Disease Colombia Trial. The investigational drug, crenezumab, did not statistically significantly slow cognitive decline in patients with a specific genetic mutation linked to early-onset Alzheimer’s. Although numerical advantages over placebo were noted, they lack statistical significance. The trial, involving 252 participants, reported no new safety issues. Initial data will be shared at the Alzheimer's Association International Conference on August 2, 2022.
AC Immune announced participation in the 2022 Jefferies Healthcare Conference from June 8-10, 2022, in New York. CEO Andrea Pfeifer will discuss the company's progress in neurodegenerative disease treatments during a fireside chat on June 9 at 8:00 am EDT. The company aims to shift the treatment paradigm towards early diagnosis and disease prevention. Key milestones include the reporting of Phase 2 results for crenezumab in an Alzheimer's prevention trial, expected soon. AC Immune is focused on advancing precision medicine through its innovative therapeutic and diagnostic pipeline.
FAQ
What is the current stock price of AC Immune (ACIU)?
What is the market cap of AC Immune (ACIU)?
